Arvinas 选择 Certara D360 来提高药物发现研究的速度和效率
了解有关 D360 的更多信息
In February 2020, we announced that Certara’s discovery research relationship with Arvinas had expanded to include a greater diversity of small molecule drug discovery projects and data sources. In 2017, Arvinas switched over to D360 from their former, legacy informatics reporting system. Their growing informatics needs were not being met by their legacy system. They wanted to easily view and manipulate data into tables, conduct SAR analysis, and have options for form and spreadsheet views, all within their informatics platform. After seeing D360’s capabilities, the Arvinas team knew that it would meet their current and ongoing needs, and they selected to move forward with D360 and recently expanded their use of D360.
Like most non-enterprise and agile biopharmaceutical companies, Arvinas does not have a large IT team and does not desire heavy IT infrastructure. To meet the ever growing demand of simplifying deployment and maintenance of solutions, D360 was implemented and hosted in the cloud. They have increased the number of data sources and complexity of data, which are now seamlessly integrated with D360 providing complete transparency to their end users. They currently have approximately 70 scientists using D360, running over 700 distinct D360 queries.
Arvinas is the pioneer and clinical-stage leader in the exciting, new area of targeted protein degradation. Its proprietary PROTAC® (proteolysis-targeting chimera) protein degraders are chimeric, modular small molecules, which harness the body’s natural protein disposal system, the ubiquitin‐proteasome system, to induce the degradation of disease‐causing proteins. Arvinas’ current drug discovery focus areas include metastatic prostate cancer, locally-advanced or metastatic breast cancer, and neurodegenerative diseases.
About D360
D360™ 是行业领先的科学数据信息学平台，在全球范围内为 6,000 多名小分子和生物制剂发现与临床前安全领域的发现研究科学家所使用。它提供自助服务数据访问以及一体化的分析和可视化解决方案。To learn more, visit www.certara.com/d360
